CRYSTALLINE (17ALPHA)-17 HYDROXY-11-METHYLENE-19-NORPREGNA-4,15-DIENE-20-YN-3-ONE (ORG 30659) AND THE PROCESS AND USE OF MAKING THIS COMPOUND FOR ORAL CONTRACEPTIVES AND HORMONE REPLACEMENT THERAPY

摘要

The disclosed invention resides in the polymorphism found with the progestagenic steroidal compound (17alpha)-17-hydroxy-11-methylene-19-norpregna-4,15-diene-20-yn-3-one. More particularly, the invention resides in crystalline forms of said compound having unexpectedly favorable thermodynamic stability. These crystalline compounds, which can be suitably described with reference to spectral data, can advantageously be employed as an active ingredient in solid pharmaceutical compositions. The crystalline compounds can be used in oral contraceptives and in hormone replacement therapy (HRT).